Loading organizations...
Hengdian Group Capital (HgC) operates as the dedicated investment and corporate development arm of the larger Hengdian Group. It constructs and manages a diverse portfolio of strategic investments, employing various capital deployment strategies across multiple sectors. As the group's sole vehicle for external capital allocation and inorganic growth initiatives, HgC plays a crucial role in identifying and nurturing opportunities that align with its parent company's expansive business interests.
The foundation of this investment entity traces back to the establishment of its parent, Hengdian Group, which was founded in 1975 by Xu Wenrong in Hengdian, Zhejiang. Over decades, the Hengdian Group evolved into a substantial private enterprise. Hengdian Group Capital itself was later instituted in June 2017 as a wholly-owned subsidiary, created to centralize and strategically manage the group's growing investment activities and corporate development mandates.
Hengdian Group Capital primarily serves the strategic objectives of its parent company, supporting its diverse business lines through focused capital and expertise. Its vision centers on broadening and deepening the Hengdian Group's influence across its various industries and into new ventures. The firm consistently works to identify and back enterprises that promise to generate sustainable value and contribute to the long-term strategic evolution of the entire Hengdian ecosystem.
Hengdian Group Capital has 1 tracked investment across 1 company. The latest tracked deal is $287.0M Series D in Jixing Pharmaceuticals in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 26, 2026 | Jixing Pharmaceuticals | $287.0M Series D | — | Adage Capital Management, HBM Healthcare Investments, Invus, RA Capital Management, Roderick Wong, Silver ARC Private Capital, SR ONE, SymBiosis, TCGX |